A Review on the Text Segmentation Techniques

mann, Harpreet; Marwaha, Chetan

doi:10.18535/ijecs/v6i3.31

Cited by 2 publications

(2 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chlorpromazine (CPZ), for example, is used to treat psychotic disorders, such as schizophrenia or manic-depression, in adults. 66 Some studies reported that phenothiazine derivatives, including CPZ, may affect the formation of CCVs and then inhibit CME. 67,68 Similarly, during viral infection, chloroquine inhibits the formation and functioning of CCVs and its analogs inhibit the acidification of endosomes.…”

Section: Pharmacological Inhibitorsmentioning

confidence: 99%

Insight into the role of clathrin‐mediated endocytosis inhibitors in SARS‐CoV‐2 infection

AlKafaas

Abdallah

Ghosh

et al. 2022

Reviews in Medical Virology

View full text Add to dashboard Cite

Emergence of SARS‐CoV‐2 variants warrants sustainable efforts to upgrade both the diagnostic and therapeutic protocols. Understanding the details of cellular and molecular basis of the virus–host cell interaction is essential for developing variant‐independent therapeutic options. The internalization of SARS‐CoV‐2, into lung epithelial cells, is mediated by endocytosis, especially clathrin‐mediated endocytosis (CME). Although vaccination is the gold standard strategy against viral infection, selective inhibition of endocytic proteins, complexes, and associated adaptor proteins may present a variant‐independent therapeutic strategy. Although clathrin and/or dynamins are the most important proteins involved in CME, other endocytic mechanisms are clathrin and/or dynamin independent and rely on other proteins. Moreover, endocytosis implicates some subcellular structures, like plasma membrane, actin and lysosomes. Also, physiological conditions, such as pH and ion concentrations, represent an additional factor that mediates these events. Accordingly, endocytosis related proteins are potential targets for small molecules that inhibit endocytosis‐mediated viral entry. This review summarizes the potential of using small molecules, targeting key proteins, participating in clathrin‐dependent and ‐independent endocytosis, as variant‐independent antiviral drugs against SARS‐CoV‐2 infection. The review takes two approaches. The first outlines the potential role of endocytic inhibitors in preventing endocytosis‐mediated viral entry and its mechanism of action, whereas in the second computational analysis was implemented to investigate the selectivity of common inhibitors against endocytic proteins in SARS‐CoV‐2 endocytosis. The analysis revealed that remdesivir, methyl‐β‐cyclodextrin, rottlerin, and Bis‐T can effectively inhibit clathrin, HMG‐CoA reductase, actin, and dynamin I GTPase and are more potent in inhibiting SARS‐CoV‐2 than chloroquine. CME inhibitors for SARS‐CoV‐2 infection remain understudied.

show abstract

Section: Pharmacological Inhibitorsmentioning

confidence: 99%

Insight into the role of clathrin‐mediated endocytosis inhibitors in SARS‐CoV‐2 infection

AlKafaas

Abdallah

Ghosh

et al. 2022

Reviews in Medical Virology

View full text Add to dashboard Cite

show abstract

“…Many of the drugs synthesized were originally designed to treat other indications, and their final designation was still the matter of chance finding [ 2 ]. The discovery of chlorpromazine as an antipsychotic, for example, is often described as ‘serendipitous’, as it was originally synthesized for nausea and allergies; however, it was observed that it induced calmness when given to patients [ 3 ]. Other examples include the anxiolytic meprobamate, which was first used as an antimicrobial therapy [ 4 ], or the MAOI antidepressants that were first tried in tuberculosis [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside

Barabássy,

Dombi,

Németh

2024

IJMS

View full text Add to dashboard Cite

Until the late 1800s, drug development was a chance finding based on observations and repeated trials and errors. Today, drug development must go through many iterations and tests to ensure it is safe, potent, and effective. This process is a long and costly endeavor, with many pitfalls and hurdles. The aim of the present review article is to explore what is needed for a molecule to move from the researcher bench to the patients’ bedside, presented from an industry perspective through the development program of cariprazine. Cariprazine is a relatively novel antipsychotic medication, approved for the treatment of schizophrenia, bipolar mania, bipolar depression, and major depression as an add-on. It is a D3-preferring D3-D2 partial agonist with the highest binding to the D3 receptors compared to all other antipsychotics. Based on the example of cariprazine, there are several key factors that are needed for a molecule to move from the researcher bench to the patients’ bedside, such as targeting an unmet medical need, having a novel mechanism of action, and a smart implementation of development plans.

show abstract

A Review on the Text Segmentation Techniques

Cited by 2 publications

References 10 publications

Insight into the role of clathrin‐mediated endocytosis inhibitors in SARS‐CoV‐2 infection

Insight into the role of clathrin‐mediated endocytosis inhibitors in SARS‐CoV‐2 infection

D3 Receptor-Targeted Cariprazine: Insights from Lab to Bedside

Contact Info

Product

Resources

About